Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit

Introduction: Immune checkpoint inhibitors (ICIs) are a major breakthrough in cancer treatment. Their increasingly frequent use leads to an uprising incidence of immune-related adverse events (irAEs). Among those, myocarditis is the most reported fatal cardiovascular irAE, frequently associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Deharo, François, Carvelli, Julien, Cautela, Jennifer, Garcia, Maxime, Sarles, Claire, Maues de Paula, Andre, Bourenne, Jérémy, Gainnier, Marc, Bichon, Amandine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573481/
https://www.ncbi.nlm.nih.gov/pubmed/36233479
http://dx.doi.org/10.3390/jcm11195611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573481/
https://www.ncbi.nlm.nih.gov/pubmed/36233479
http://dx.doi.org/10.3390/jcm11195611

Ejemplares similares